Summary of Study ST000488

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000370. The data can be accessed directly via it's Project DOI: 10.21228/M87604 This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000488
Study TitleSleep apnea and cardiovascular metabiltes carnitine, tma, tmao, betain, choline in plasma
Study SummarySleep apnea and cardiovascular metabiltes carnitine, tma, tmao, betain, choline in plasma
Mayo Clinic
LaboratoryMayo Clinic Metabolomics Resource Core
Last NamePak
First NameVictoria
Submit Date2016-10-14
Analysis Type DetailLC-MS
Release Date2018-10-10
Release Version1
Victoria Pak Victoria Pak application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000370
Project DOI:doi: 10.21228/M87604
Project Title:Mayo Metabolomics Pilot and Feasibility Award: Mechanisms of sleep apnea and cardiovascular disease
Project Type:MS targeted analysis
Project Summary:Targeted Metabolic and Biological Markers of Sleepiness Symptoms in Sleep apnea and cardiovascular disease
Institute:Mayo Clinic
Laboratory:Mayo Clinic Metabolomics Resource Core
Last Name:Pak
First Name:Victoria


Subject ID:SU000509
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human


Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Disease
SA025392ms5666-12cardiovascular disease
SA025393ms5666-11cardiovascular disease
SA025394ms5666-14cardiovascular disease
SA025395ms5666-16cardiovascular disease
SA025396ms5666-1cardiovascular disease
SA025397ms5666-10cardiovascular disease
SA025398ms5666-15cardiovascular disease
SA025399ms5666-13cardiovascular disease
SA025400ms5666-3cardiovascular disease
SA025401ms5666-9cardiovascular disease
SA025402ms5666-2cardiovascular disease
SA025403ms5666-4cardiovascular disease
SA025404ms5666-5cardiovascular disease
SA025405ms5666-8cardiovascular disease
SA025406ms5666-7cardiovascular disease
SA025407ms5666-6cardiovascular disease
SA025408ms5666-31sleep apnea
SA025409ms5666-30sleep apnea
SA025410ms5666-29sleep apnea
SA025411ms5666-32sleep apnea
SA025412ms5666-36sleep apnea
SA025413ms5666-28sleep apnea
SA025414ms5666-35sleep apnea
SA025415ms5666-34sleep apnea
SA025416ms5666-33sleep apnea
SA025417ms5666-19sleep apnea
SA025418ms5666-21sleep apnea
SA025419ms5666-20sleep apnea
SA025420ms5666-18sleep apnea
SA025421ms5666-17sleep apnea
SA025422ms5666-22sleep apnea
SA025423ms5666-23sleep apnea
SA025424ms5666-26sleep apnea
SA025425ms5666-25sleep apnea
SA025426ms5666-24sleep apnea
SA025427ms5666-27sleep apnea
Showing results 1 to 36 of 36


Collection ID:CO000503
Collection Summary:For the metabolic markers, 9 ml blood will be drawn into 3 EDTA tubes (3 ml each) and gently centrifuged at 4°C for 10 min; plasma aliquots were immediately frozen and stored at -80 °C; will be stored at -80ºC in the CTRC until all samples are collected and then sent to Mayo Clinic Metabolomics Core via LC-MS/MS for simultaneous detection and quantification of metabolites for analyses.
Sample Type:Blood


Treatment ID:TR000523
Treatment Summary:Recruitment of subjects will take place from the clinic population in collaboration with the Penn Sleep Center. Patients newly diagnosed with OSA will be solicited for via an overnight sleep study, which is general monitoring of sleep and variety of body functions during sleep. This includes brain (EEG), eye (EOG), and muscle activity and heart rhythm. The diagnosis of OSA will be established by full sleep study. First, the PI will screen for eligibility and obtain informed consent. We will assess height, weight, medical history, demographics. EDS will be measured subjectively on the night of enrollment in the study and determined using the Epworth Sleepiness Scale. The information regarding gender, BMI, smoking, age, medications (name/duration/frequency), and presence of comorbidities (e.g. hypertension, CVD defined by doctor diagnosis of myocardial infarction, stroke, or heart failure) will then be obtained via the electronic medical record. We will also ask subjects whether they exercise by asking participants the yes/no question: “During the past month, did you participate in any physical activities or exercises?” Second, the subject will undergo diagnostic PSG and we will enforce fasting prior to bedtime. Third, biological samples will be collected in the morning after the sleep study. Patients who have agreed to participate will undergo a blood draw (20 ml) and urine collection (30 ml) on the morning after PSG. Laboratory analysis of the biological samples will be conducted in collaboration with the Clinical Translation Research Center (CTRC). Finally, subjects will have 1 or 2 practice sessions with the PVT prior to administration of the task. PVT test will be conducted 3 times, at approximately 10:00, 12:00, and 14:00 and automatically scored. This will be done on the day after the sleep study.

Sample Preparation:

Sampleprep ID:SP000516
Sampleprep Summary:TMAO panel

Combined analysis:

Analysis ID AN000754
Analysis type MS
Chromatography type HILIC
Chromatography system Cohesive TX2
Column Altma HP HILIC (150 x 2.1mm,5um)
MS instrument type Triple quadrupole
MS instrument name ABI Sciex 6500 QTrap
Units micromolar


Chromatography ID:CH000540
Instrument Name:Cohesive TX2
Column Name:Altma HP HILIC (150 x 2.1mm,5um)
Chromatography Type:HILIC


MS ID:MS000666
Analysis ID:AN000754
Instrument Name:ABI Sciex 6500 QTrap
Instrument Type:Triple quadrupole